Kidney transplant recipients kidney transplant
Conditions
Interventions
kidney transplant recipients receiving concomitant (within 2 hours) antacid with tacrolimus dose,kidney transplant recipients receiving an antacid administered 2 hours or more apart from tacrolimus do
antacid concomitant group,separate timing group,no antacid group
Sponsors
Department of Pharmacy Practice, Chulalongkorn University
Doctor Kasem Foundation
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1) Aged 18 years or more and provided informed consent to participate in the study. 2) KTRs who were admitted to the inpatient ward at Rajavithi Hospital. 3) KTRs receiving twice-daily oral tacrolimus as the primary immunosuppressive regimen 4) Patients with available tacrolimus trough concentration measurements at steady state
Exclusion criteria
Exclusion criteria: 1) Multiorgan transplant recipients 2) Patients diagnosed with active liver disease, including viral hepatitis, hepatocellular carcinoma, or liver cirrhosis, or with liver enzyme levels higher than 3 times the upper limit of normal values 3) Patients receiving clinically significant drug interactions affecting tacrolimus pharmacokinetics, except for the study antacids, prednisolone, proton pump inhibitors, and diltiazem 4) Patients receiving combination antacid or gastric mucosal protective suspensions containing aluminum hydroxide, magnesium hydroxide, and simethicone, or antacid/laxative liquid formulations containing magnesium hydroxide 5) Patients with incomplete medical records 6) Patients who died prior to study initiation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| tacrolimus trough concentration to dose ratio morning trough whole blood concentration to dose ratio | — |
Secondary
| Measure | Time frame |
|---|---|
| tacrolimus trough concentration morning trough CMIA | — |
Countries
Thailand
Contacts
Public Contactsaowarat phacheroen
Rajavithi Hospital
Outcome results
None listed